Comparative Pharmacology
Head-to-head clinical analysis: OXSORALEN versus OXSORALEN ULTRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXSORALEN versus OXSORALEN ULTRA.
OXSORALEN vs OXSORALEN-ULTRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Psoralen intercalates into DNA and upon UVA exposure forms covalent crosslinks between pyrimidine bases, inhibiting DNA synthesis and cell proliferation.
Oxsoralen-Ultra (methoxsalen) is a psoralen derivative that, upon photoactivation by UVA radiation, forms covalent cross-links with DNA, thereby inhibiting DNA synthesis and cell division. It also suppresses cutaneous immune responses and reduces epidermal cell turnover.
0.6 mg/kg orally once daily, 2 hours before UV-A exposure, or 0.4 mg/kg orally 2 hours before psoralen plus UV-A (PUVA) therapy. For topical use, a 1% lotion is applied 2 hours prior to UV-A exposure.
0.6 mg/kg orally as a single dose 2 hours prior to PUVA therapy, administered 3 times per week on non-consecutive days.
None Documented
None Documented
Approximately 2-5 hours for parent drug; clinical effect persists longer due to epidermal DNA binding.
2 hours (terminal) with clinical context: elimination is rapid; no accumulation with q3-5d dosing.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for the majority of metabolites, though exact percentage not well defined.
Primarily renal: 90-95% as metabolites within 24 hours; minimal biliary/fecal (<5%).
Category C
Category C
Psoralen
Psoralen